- Marina Pavlovic Rivas's company, Eli Health, has successfully raised $12 million in a new funding round.
- With this latest boost, their total funding now stands at $20 million. The company plans to use these funds to test out a new platform that helps measure cortisol levels in the body.
Eli Health has successfully raised $12 million in its Series A funding round, and they’ve also started testing their new platform to measure cortisol levels. With this latest funding, the company's total now stands at $20 million. The recent investment was led by Thrive Venture Fund, a BDC Capital fund that focuses on supporting women-led businesses.
Several other firms also participated which includes existing investor Muse Capital, whose founding partner, Assia Grazioli-Venier, is on Eli Health's board. In addition, Eli Health co-founder and CEO Marina Pavlovic Rivas said in a statement to SBI, “This milestone is extremely meaningful, because to get to this point, it was close to six years of [research and development]. For the first time, people are able to measure their hormones instantly, and this funding enables us to accelerate access to the product and to expand to other biomarkers.”
Moreover, Hormometer is the flagship product of the company that tests saliva for key hormones like cortisol as well as progesterone via a collection device. Later, the product will leverage computer vision models to analyze the sample, returning results and AI-powered trends/recommendations to its mobile app through one’s phone camera.
"One in three adults are affected by dysregulation when it comes to cortisol, and that’s true across gender, across ages. We’re starting with that focus, and progesterone will follow shortly,” Marina added.
